+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: is it really safe?



Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: is it really safe?



Gastric Cancer 20(6): 978-986



Papillary adenocarcinoma of the stomach has been treated according to the same endoscopic submucosal dissection (ESD) indication criteria as other differentiated-type adenocarcinomas. We aimed to compare lymph node metastasis (LNM) in patients with early gastric cancer (EGC) with papillary adenocarcinoma (EGC-P) with that in patients with EGC with nonpapillary adenocarcinoma (EGC-NP) and to consider the potential limitation of current ESD indication criteria in the treatment of EGC-P. In total, 1583 patients who underwent gastrectomy for EGC from 2005 to 2014 were included. Clinicopathologic characteristics of 56 patients with EGC-P were compared with those of 1527 patients with EGC-NP. The safety of ESD was evaluated, by application of current ESD indication criteria to EGC-P. The frequency of submucosal invasion was significantly higher in EGC-P than in both EGC-NP with differentiated-type histologic appearance and EGC-NP with undifferentiated-type histologic appearance (71.4% vs 50.8% and 37.6%, respectively). In addition, the frequency of LNM in EGC-P was 17.9%, higher than that in both EGC-NP with differentiated-type histologic appearance and EGC-NP with undifferentiated-type histologic appearance (9.7% and 11.1%, respectively). When the current ESD indication criteria were applied to the 56 patients with EGC-P, 17 patients met the current indications. Of these patients, two (11.8%) had LNM and three (17.6%) had lymphovascular invasion (LVI). When LNM and LVI were combined, one of seven patients (16.7%) meeting the absolute ESD indications and three of ten patients (30.0%) meeting the expanded ESD indications would not be cured after ESD. The use of ESD should be more carefully applied in patients with EGC-P meeting the ESD indication criteria, especially the expanded indication criteria, after pretreatment workup compared with other differentiated-type adenocarcinomas, owing to the higher frequencies of submucosal invasion, LNM, and LVI in EGC-P.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059680952

Download citation: RISBibTeXText

PMID: 28271420

DOI: 10.1007/s10120-017-0709-6


Related references

Is endoscopic submucosal dissection safe for papillary adenocarcinoma of the stomach?. World Journal of Gastroenterology 21(13): 3944-3952, 2015

Sa1868 Is Endoscopic Submucosal Dissection Safe for Papillary Adenocarcinoma of Stomach?. Gastroenterology 146(5): S-316, 2014

Endoscopic submucosal dissection of papillary adenocarcinoma of stomach; protocol for a systematic review and meta-analysis. Medicine 97(52): E13905, 2018

Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: low curative resection rate but favorable long-term outcomes after curative resection. Gastric Cancer 22(2): 363-368, 2019

Propofol sedation without endotracheal intubation is safe for endoscopic submucosal dissection in the esophagus and stomach. United European Gastroenterology Journal 7(3): 405-411, 2019

Endoscopic submucosal dissection of squamous cell carcinoma in the upper stomach 5 years after chemoradiotherapy for adenocarcinoma. Clinical Journal of Gastroenterology 7(4): 310-315, 2014

Endoscopic submucosal excavation (ESE) is a safe and useful technique for endoscopic removal of submucosal tumors of the stomach and the esophagus in selected cases. Zeitschrift für Gastroenterologie 53(6): 573-578, 2016

Clinical and Pathological Challenges in the Diagnosis of Gastric-Type Differentiated Adenocarcinoma in the Stomach: A Study of Endoscopic Submucosal Dissection Cases. Digestion 99(4): 301-309, 2019

Gastric adenocarcinoma with a submucosal cyst treated by endoscopic submucosal dissection (ESD). Endoscopy 41(Suppl. 2): E267-E268, 2010

Clinicopathological features of Siewert type II adenocarcinoma: comparison of gastric cardia adenocarcinoma and Barrett's esophageal adenocarcinoma following endoscopic submucosal dissection. Gastric Cancer 20(4): 663-670, 2017

Randomized controlled trial comparing submucosal endoscopy with mucosal resection and endoscopic submucosal dissection in the esophagus and stomach: Animal study. Digestive Endoscopy 30(1): 65-70, 2018

Efficacy and adverse events of EMR and endoscopic submucosal dissection for the treatment of colon neoplasms: a meta-analysis of studies comparing EMR and endoscopic submucosal dissection. Gastrointestinal Endoscopy 81(3): 583-595, 2015

Implementation of endoscopic submucosal dissection for early upper gastrointestinal tract cancer after primary experience in colorectal endoscopic submucosal dissection. Endoscopy International Open 7(4): E446-E451, 2019

Endoscopic submucosal dissection of stomach neoplasms after unsuccessful endoscopic resection. Digestive and Liver Disease 39(6): 566-571, 2007

Endoscopic submucosal tunnel dissection and endoscopic submucosal dissection for large superficial esophageal squamous cell neoplasm: efficacy and safety study to guide future practice. Surgical Endoscopy 32(6): 2814-2821, 2018